Thera-SAbDab

RISANKIZUMAB

>   Structural Summary
TherapeuticRisankizumab
TargetIL23A
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTDQTIHWMRQAPGQGLEWIGYIYPRDDSPKYNENFKGKVTITADKSTSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVADYFCHQYSSYPFTFGSGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedAbbVie, Boehringer Ingelheim
Conditions ApprovedErythrodermic psoriasis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis
Conditions ActiveCrohn's disease, Ulcerative colitis, Atopic dermatitis
Conditions DiscontinuedPsoriasis, Ankylosing spondylitis, Asthma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]